Literature DB >> 26523543

Perineural Invasion in Prostate Cancer Is More Frequently Detected by Multiparametric MRI Targeted Biopsy Compared With Standard Biopsy.

Jennifer B Gordetsky1, Jeffrey W Nix, Soroush Rais-Bahrami.   

Abstract

Multiparametric magnetic resonance imaging (MP-MRI) incorporates high-resolution imaging to aid in the detection of lesions suspicious for prostate cancer (PCa). MP-MRI and MRI/ultrasound (US) fusion-guided prostate biopsy has been shown to detect more clinically significant PCa. However, to date there have been no studies in fusion-guided biopsies evaluating the detection of perineural invasion. We assessed whether MRI/US fusion-guided prostate biopsies diagnosed more perineural invasion compared with standard techniques. We reviewed our prospectively maintained prostate biopsy database evaluating men who underwent MP-MRI and MRI/US fusion-guided prostate biopsy between January 2014 and June 2015. Patients underwent MP-MRI followed by 12-core standard biopsy and fusion-guided biopsies of MRI-identified lesions. Patients' clinical, radiologic, and pathologic findings were reviewed. A total of 114 patients underwent both 12-core standard biopsy and MRI/US fusion-guided prostate biopsy. The mean age and prebiopsy prostate-specific antigen of our patient cohort was 64.5 years and 10.7 ng/mL, respectively. Sixty-four of 114 (56%) patients were found to have PCa. Perineural invasion was identified in 19/64 (30%) patients. Of the patients with perineural invasion, 9 were diagnosed on the fusion biopsy only, 2 were diagnosed on standard biopsy only, and 8 were diagnosed on both standard and fusion biopsies. Perineural invasion was significantly associated with higher prostate-specific antigen and with a higher number of cores involved by cancer (P<0.05). Compared with standard biopsy, MRI/US fusion-guided prostate biopsy improves detection of perineural invasion in PCa. As perineural invasion has only been studied on standard biopsies to date, it is unclear whether this finding has the same clinical significance for MP-MRI targeted lesions.

Entities:  

Mesh:

Year:  2016        PMID: 26523543     DOI: 10.1097/PAS.0000000000000546

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  [Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis].

Authors:  Li-Zhi Lei; Yi-Kai Xu; Mei-Rong Hou; Meng-Qi He
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

Review 2.  MR/US Fusion Technology: What Makes It Tick?

Authors:  Srinivas Vourganti; Norman Starkweather; Andrij Wojtowycz
Journal:  Curr Urol Rep       Date:  2017-03       Impact factor: 3.092

Review 3.  Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning.

Authors:  Steven Sidelsky; Shaan Setia; Srinivas Vourganti
Journal:  Curr Urol Rep       Date:  2017-10-18       Impact factor: 3.092

4.  Target prostate biopsies: How best to report in synoptic format?

Authors:  Michelle R Downes; John R Srigley; Andrew Loblaw; Nathan Perlis; Sangeet Ghai; Theodorus van der Kwast
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 1.862

5.  PTEN and ERG detection in multiparametric magnetic resonance imaging/ultrasound fusion targeted prostate biopsy compared to systematic biopsy.

Authors:  Erin Baumgartner; Maria Del Carmen Rodriguez Pena; Marie-Lisa Eich; Kristin K Porter; Jeffrey W Nix; Soroush Rais-Bahrami; Jennifer Gordetsky
Journal:  Hum Pathol       Date:  2019-05-07       Impact factor: 3.466

6.  Prostate cancer management choices in patients undergoing multiparametric magnetic resonance imaging/ultrasound fusion biopsy compared to systematic biopsy.

Authors:  Jennifer B Gordetsky; Benjamin Saylor; Sejong Bae; Jeffrey W Nix; Soroush Rais-Bahrami
Journal:  Urol Oncol       Date:  2018-03-08       Impact factor: 2.954

Review 7.  Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification.

Authors:  Kyle H Gennaro; Kristin K Porter; Jennifer B Gordetsky; Samuel J Galgano; Soroush Rais-Bahrami
Journal:  Diagnostics (Basel)       Date:  2018-11-30

8.  Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively.

Authors:  Amar S Ahmad; Vishnu Parameshwaran; Luis Beltran; Gabrielle Fisher; Bernard V North; David Greenberg; Geraldine Soosay; Henrik Møller; Peter Scardino; Jack Cuzick; Daniel M Berney
Journal:  Oncotarget       Date:  2018-04-17

9.  DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy.

Authors:  Caleb R Dulaney; Soroush Rais-Bahrami; Debra Della Manna; Jennifer B Gordetsky; Jeffrey W Nix; Eddy S Yang
Journal:  Oncotarget       Date:  2017-07-10

10.  Detection of extraprostatic disease and seminal vesicle invasion in patients undergoing magnetic resonance imaging-targeted prostate biopsies.

Authors:  Erin M Baumgartner; Kristin K Porter; Jeffrey W Nix; Soroush Rais-Bahrami; Jennifer B Gordetsky
Journal:  Transl Androl Urol       Date:  2018-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.